AU2020263948B2 - mRNA formulation - Google Patents

mRNA formulation

Info

Publication number
AU2020263948B2
AU2020263948B2 AU2020263948A AU2020263948A AU2020263948B2 AU 2020263948 B2 AU2020263948 B2 AU 2020263948B2 AU 2020263948 A AU2020263948 A AU 2020263948A AU 2020263948 A AU2020263948 A AU 2020263948A AU 2020263948 B2 AU2020263948 B2 AU 2020263948B2
Authority
AU
Australia
Prior art keywords
trimix
mrna
pseudouridine
mod
anyone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020263948A
Other languages
English (en)
Other versions
AU2020263948A1 (en
Inventor
Sanne BEVERS
Stefaan De Koker
Peter Tomme
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vrije Universiteit Brussel
Etherna Immunotherapies NV
Original Assignee
Vrije Universiteit Brussel
Etherna Immunotherapies NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vrije Universiteit Brussel, Etherna Immunotherapies NV filed Critical Vrije Universiteit Brussel
Publication of AU2020263948A1 publication Critical patent/AU2020263948A1/en
Assigned to VRIJE UNIVERSITEIT BRUSSEL, ETHERNA IMMUNOTHERAPIES NV reassignment VRIJE UNIVERSITEIT BRUSSEL Request for Assignment Assignors: ETHERNA IMMUNOTHERAPIES NV
Application granted granted Critical
Publication of AU2020263948B2 publication Critical patent/AU2020263948B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020263948A 2019-04-26 2020-04-24 mRNA formulation Active AU2020263948B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19171323 2019-04-26
EP19171323.9 2019-04-26
PCT/EP2020/061477 WO2020216911A1 (en) 2019-04-26 2020-04-24 Mrna formulation

Publications (2)

Publication Number Publication Date
AU2020263948A1 AU2020263948A1 (en) 2021-12-23
AU2020263948B2 true AU2020263948B2 (en) 2026-06-25

Family

ID=66290283

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020263948A Active AU2020263948B2 (en) 2019-04-26 2020-04-24 mRNA formulation

Country Status (12)

Country Link
US (1) US20220362360A1 (enExample)
EP (1) EP3958893A1 (enExample)
JP (1) JP7650001B2 (enExample)
KR (1) KR20220023340A (enExample)
CN (1) CN114096272B (enExample)
AU (1) AU2020263948B2 (enExample)
BR (1) BR112021021262A2 (enExample)
CA (1) CA3138011A1 (enExample)
IL (1) IL287560B2 (enExample)
MX (1) MX2021013018A (enExample)
SG (1) SG11202111720TA (enExample)
WO (1) WO2020216911A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7496623B2 (ja) * 2019-01-04 2024-06-07 イーザアールエヌーエー イムノセラピーズ エンヴェー ｍＲＮＡワクチン
US20220143161A1 (en) * 2019-03-13 2022-05-12 Etherna Immunotherapies Nv Mrna vaccine
CN119701015A (zh) * 2023-09-26 2025-03-28 深圳瑞吉生物科技有限公司 一种细胞因子mRNA组合药物及其应用
CN121873266A (zh) * 2026-03-18 2026-04-17 北京悦康科创医药科技股份有限公司 一种增强肿瘤疫苗免疫原性的嵌合多肽及其制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180133311A1 (en) * 2007-09-14 2018-05-17 Vrije Universiteit Brussel Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2201100E (pt) * 2007-09-14 2016-06-03 Univ Brussel Vrije Aperfeiçoamento da capacidade estimulatória de células t das células que apresentam antígeno humano e o seu uso na vacinação
US20130108663A1 (en) * 2007-09-14 2013-05-02 Vrije Universiteit Brussel Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and their use in vaccination
EP3173474A1 (en) * 2007-09-14 2017-05-31 Vrije Universiteit Brussel Enhancing the t-cells stimulatory capacity of human antigen presenting cells and their use in vaccination
WO2015071295A1 (en) 2013-11-12 2015-05-21 Vrije Universiteit Brussel Rna transcription vector and uses thereof
DK4276189T3 (da) * 2015-09-21 2026-05-26 Trilink Biotechnologies Llc Initierende oligonukleotidprimere med kappe til syntesering af 5'-ende RNA'er med kappe
EP3359670B2 (en) 2015-10-05 2024-02-14 ModernaTX, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
MA47515A (fr) * 2017-02-16 2019-12-25 Modernatx Inc Compositions immunogènes très puissantes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180133311A1 (en) * 2007-09-14 2018-05-17 Vrije Universiteit Brussel Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SRIRAM VAIDYANATHAN ET AL, 20TH ASCGT ANNUAL MEETING, MAY 2017, 13 May 2017 (2017-05-13), Retrieved from the Internet *

Also Published As

Publication number Publication date
BR112021021262A2 (pt) 2021-12-21
SG11202111720TA (en) 2021-11-29
CN114096272B (zh) 2024-08-06
EP3958893A1 (en) 2022-03-02
CN114096272A (zh) 2022-02-25
WO2020216911A1 (en) 2020-10-29
JP7650001B2 (ja) 2025-03-24
IL287560B2 (en) 2026-02-01
US20220362360A1 (en) 2022-11-17
AU2020263948A1 (en) 2021-12-23
MX2021013018A (es) 2022-03-11
CA3138011A1 (en) 2020-10-29
IL287560B1 (en) 2025-10-01
JP2022532038A (ja) 2022-07-13
KR20220023340A (ko) 2022-03-02
IL287560A (en) 2021-12-01

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ETHERNA IMMUNOTHERAPIES NV

Free format text: FORMER APPLICANT(S): ETHERNA IMMUNOTHERAPIES NV

Owner name: VRIJE UNIVERSITEIT BRUSSEL

Free format text: FORMER APPLICANT(S): ETHERNA IMMUNOTHERAPIES NV